期刊文献+

人肾癌鸡胚模型的建立及其肿瘤生物学特性的研究 被引量:7

Establishment and biological characteristics of a human renal cell carcinoma model on chick embryo chorioallantoic membrane
下载PDF
导出
摘要 目的建立人肾癌鸡胚模型,探讨其形态及生物学特性。方法将肾癌细胞系RLC-310接种于鸡胚绒毛尿囊膜,观察影响肾癌鸡胚移植瘤成活的因素、移植瘤生长特性、形态学特征和生物学性状。结果成功建立了人肾癌鸡胚移植瘤模型;移植瘤易于生长并具有较强的血管诱导作用;光镜下移植瘤具有与人肾癌类似的组织结构。结论该模型容易建立,能动态观察肾癌诱导血管生成的全过程,可用于肾癌的实验研究。 Objective To establish a human renal cell carcinoma(RCC) model on chick embryo chorioallantoic membrane and to study its biological characteristics.Methods Human RCC cell line RLC-310 was implanted on the chick embryo chorioallantoic membrane.The factors which affect the implanted tumors and the morphological and biological characteristics of the tumors were studied.Results Human RCC model was successfully established.The implanted tumors grew easily on the chick embryo chorioallantoic membrane and had a strong trend of angiogenesis and a structure similar to that of human RCC with microscopic verification.Conclusion This model can be easily duplicated and used in experiment research on human renal cell carcinoma.
出处 《西安交通大学学报(医学版)》 CAS CSCD 北大核心 2012年第1期68-70,共3页 Journal of Xi’an Jiaotong University(Medical Sciences)
基金 山东省自然科学基金资助课题(No.Y2006C04)~~
关键词 肾癌 鸡胚绒毛尿囊膜 动物模型 血管生成 renal cell carcinoma chick embryo chorioallantoic membrane animal model angiogenesis
  • 相关文献

参考文献5

二级参考文献24

共引文献43

同被引文献91

  • 1于猛,热增才旦,杨科,贾红梅,张宏武,王英锋,邹忠梅.沙苑子苷A通过抑制血管生成抗肿瘤作用研究[J].药物评价研究,2020,0(1):21-26. 被引量:10
  • 2陈磊,苏波,牛彪,阮俊程,郭跃,王德慧,顾玉林,田大勇.自研培养基在人用鸡胚狂犬病疫苗中的应用[J].微生物学免疫学进展,2020,0(1):56-62. 被引量:1
  • 3陈杰,刘庆勇,阮喜云,张士宝,张建军,李宗武,杨广笑,王全颖.NT4-TAT-6×His-VHLβ结构域肾癌抑制融合肽cDNA克隆的构建[J].山东大学学报(医学版),2009,47(7):32-36. 被引量:1
  • 4王世军,孙静,张栋,郭继龙,简隆磊,刘铠.鸡胚尿囊膜血管生长的特点及观测方法[J].生物医学工程研究,2004,23(1):38-40. 被引量:16
  • 5Eheman C,Henley S J, Ballard-Barbash R,et al. AnnualReport to the Nation on the status of cancer, 1975-2008,featuring cancers associated with excess weight and lack ofsufficient physical activity [ J]. Cancer, 2012,118 (9):2338-2366.
  • 6Weikert S, Ljungberg B. Contemporary epidemiology ofrenal cell carcinoma : perspectives of primary prevention[J]. World J Urol, 2010,28(3) :247- 252.
  • 7Ratain M J, Eisen T,Stater W M, et al. PhaseHplacebo-controlled randomized discontinuation trial of sorafinib inpatients with metastatic renal cell carcinoma[ J]. J ClinOncol, 2006, 24(16) :2505-2512.
  • 8Motzer R J, Hutson T E,Tomczak P, et al. Sunitinibversus interferon alfa in metastatic renal-cell carcinoma[J]. N Engl J Med, 2007,356(2) :115-124.
  • 9Sternberg C N, Davis I D, Mardiak J, et al. Pazopanib inlocally advanced or metastatic renal cell carcinoma : re-sults of a randomized phase 皿 trial [ J]. J Clin Oncol,2010,28(6) :1061-1068.
  • 10Ravaud A, Hawkins R, Gardner J P, et al. Lapatinibversus hormone therapy in patients with advanced renalcell carcinoma; a randomized phase M clinical trial[ J].J Clin Oncol, 2008,26(14) :2285-2291.

引证文献7

二级引证文献6

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部